Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine
Patent extends proprietary position of M207 to 2037
View HTML
Toggle Summary Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on January 26, 2018
View HTML
Toggle Summary Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
Issuance Will Extend Patent Life of M207 to 2037
View HTML
Toggle Summary Zosano Announces Resignation of Bruce Steel from Board of Directors
FREMONT, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today
View HTML
Toggle Summary Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference
FREMONT, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update
First patient enrolled in long term safety study in November 2017 Phase 2/3 data presented at International Headache Society in September Clinical results published in two leading scientific journals Access to capital expanded to fund Long-term Safety Study FREMONT, Calif., Nov.
View HTML
Toggle Summary Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine
FREMONT, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update
FREMONT, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML
Toggle Summary Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital
FREMONT, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today
View HTML
Toggle Summary Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia
FREMONT, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML